← boardnext 2028-08-31next 2028-12
GRFS
Grifols Biologicals, LLCdistress 0/10 · well-funded / low risk$7.59-4%today-30% from 52w high
Lead: Antithrombin III Deficiency
Revenue
$1700M
Liquidity
$1367M
Runway
—
Shares 1y
—
Price & events
-15.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.6%
1D
+3.6%
1W
+7.2%
1M
-3.7%
3M
-16.5%
6M
-20.6%
1Y
+1.0%
2Y
-48.5%
5Y
-57.6%
All
Overview
- Volume
- 44.12K
- 52 Week Range
- $7.02 – $10.85
- Float Shares
- 836.24M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 58.23%
- RVOL
- 0.07x
- Beta
- 1.18
Pipeline stages · 2 programs
Gamunex-C, 10% Injectable Solution
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Plasma-derived AT-III concentrate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-08-31 Estimated 50% readout ~2028-11-14 | Phase 3 | Gamunex-C, 10% Injectable Solution | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 2/3 | Plasma-derived AT-III concentrate | Antithrombin III Deficiency | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-07-28earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- 2024-11-14SC 13G/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $11 (+43% upside) · 2 analysts
- 2025-12-08JP MorganNeutral
- 2025-06-17JP MorganNeutral
Competitors — Antithrombin III Deficiency
- none identified
Recent news
- 2026-07-21Grifols stock trades steady as leverage focus follows debt reduction and 2025 outlook - Ad-hoc-news.de
- 2026-07-18GRFS Technical Analysis & Stock Price Forecast - Intellectia AI
- 2026-07-16Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins - GlobeNewswire
- 2026-07-16Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins - GlobeNewswire
- 2026-07-12Grifols stock holds steady as investors weigh the business mix - Ad-hoc-news.de
- 2026-07-11Grifols stock reflects a complex plasma business amid global healthcare demand - Ad-hoc-news.de
- 2026-07-10Grifols stock holds steady as plasma specialist refines its business model - Ad-hoc-news.de
- 2026-07-07Grifols stock stays anchored to its investor profile. Focus shifts to the business model. - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.